Because CDDO-Me induces Nrf2 at low nanomolar concentrations [71], it underwent development as a promising AIM under the generic name, bardoxolone methyl for treatment of advanced chronic kidney disease (CKD) and type 2 diabetes mellitus [72]. The gene discussed is NFE2L2; the disease is diabetes mellitus.